FindTrial
Sign In

Comparing different strengths of Mifepristone in women with uterine fibroids to find the best dose for symptom relief

Comparison of different doses of mifepristone in the medical management of uterine fibroids: A prospective observational study - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/12/099469
Enrollment
100
Registered
2025-12-19
Start date
Unknown
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N938- Other specified abnormal uterine and vaginal bleeding

Interventions

Control Intervention1: Nil: Nil

Sponsors

Kavisha Bhat
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Women aged between 18-50 years Symptomatic fibroid more than or equal to 3 cm in size

Exclusion criteria

Exclusion criteria: pregnant women or women planning pregnancy Menopausal status Severe anaemia Hb less than 5 g/dl History of malignancy or Liver disease

Design outcomes

Primary

MeasureTime frame
To measure change in fibroid volume or size, change in PBAC and VAS scores, change in haemoglobin levels, incidence and severity of side effects Timepoint: Baseline, 3 months and 6 months—

Secondary

MeasureTime frame
Symptom relief Avoidance of surgery Identification of cost-effective treatment Timepoint: 6 months—

Countries

India

Contacts

Public ContactKavisha Bhat

Kasturba Medical College, Manipal

shripad.hebbar@manipal.edu9611786463

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026